Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. BridgeBio Pharma Inc shares valued at $1,279,290 were purchased by NEIL KUMAR on Aug 20 ’25. At $48.91 per share, NEIL KUMAR acquired 26,156 shares.
Also, Trimarchi Thomas sold 17,353 shares, netting a total of over 871,722 in proceeds. Following the sale of shares at $50.23 each, the insider now holds 463,318 shares.
Before that, THOMAS TRIMARCHI had added 17,353 shares to its account. In a trade valued at $871,723, the Officer bought BridgeBio Pharma Inc shares for $50.23 each.
Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of July 14, 2025, Jefferies has initiated its “Buy” rating for BBIO. Earlier on July 09, 2025, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for BBIO stock which previously was a “a Perform”.
Analyzing BBIO Stock Performance
On last trading session, BridgeBio Pharma Inc [NASDAQ: BBIO] plunged -0.06% to $48.88. The stock’s lowest price that day was $48.22, but it reached a high of $49.26 in the same session. During the last five days, there has been a drop of approximately -2.98%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 100.33%. Shares of the company reached a 52-week high of $51.86 on 08/14/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 48.31, which, if violated, would cause prices to drop to 47.75. In the upper region, resistance lies at 49.35. The next price resistance is at 49.83. RSI (Relative Strength Index) is 56.58 on the 14-day chart, showing neutral technical sentiment.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-07-31 dropping by -3.32 million shares to 18.52 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 21.83 million shares. A decline of -17.9% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.46 of the overall float, the days-to-cover ratio (short ratio) decline to 7.46.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 47.21% from the previous closing price of $48.91. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On June 17, 2025, Wolfe Research assigned a price target of “an Outperform” to the stock and initiated coverage with a $49.
